- Home
- NOVT vs MLYS Comparison
NOVT vs MLYS Comparison
Compare NOVT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOVT
- MLYS
- Stock Information
- Founded
- NOVT 1968
- MLYS 2019
- Country
- NOVT United States
- MLYS United States
- Employees
- NOVT N/A
- MLYS N/A
- Industry
- NOVT Industrial Machinery/Components
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- NOVT Miscellaneous
- MLYS Health Care
- Exchange
- NOVT Nasdaq
- MLYS Nasdaq
- Market Cap
- NOVT 3.8B
- MLYS 3.1B
- IPO Year
- NOVT N/A
- MLYS 2023
- Fundamental
- Price
- NOVT $111.77
- MLYS $37.79
- Analyst Decision
- NOVT Hold
- MLYS Strong Buy
- Analyst Count
- NOVT 1
- MLYS 6
- Target Price
- NOVT $133.00
- MLYS $44.60
- AVG Volume (30 Days)
- NOVT 454.9K
- MLYS 1.1M
- Earning Date
- NOVT 11-03-2025
- MLYS 11-10-2025
- Dividend Yield
- NOVT N/A
- MLYS N/A
- EPS Growth
- NOVT N/A
- MLYS N/A
- EPS
- NOVT 1.46
- MLYS N/A
- Revenue
- NOVT $960,311,000.00
- MLYS N/A
- Revenue This Year
- NOVT $5.06
- MLYS N/A
- Revenue Next Year
- NOVT $6.89
- MLYS N/A
- P/E Ratio
- NOVT $90.73
- MLYS N/A
- Revenue Growth
- NOVT 4.07
- MLYS N/A
- 52 Week Low
- NOVT $98.76
- MLYS $8.24
- 52 Week High
- NOVT $184.11
- MLYS $44.80
- Technical
- Relative Strength Index (RSI)
- NOVT 43.16
- MLYS 44.19
- Support Level
- NOVT $125.00
- MLYS $38.00
- Resistance Level
- NOVT $137.35
- MLYS $43.43
- Average True Range (ATR)
- NOVT 6.75
- MLYS 2.06
- MACD
- NOVT -0.02
- MLYS -0.86
- Stochastic Oscillator
- NOVT 13.59
- MLYS 10.00
About NOVT Novanta Inc.
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.